Emma Walmsley, GlaxoSmithKline CEO (via GSK)
July 1, 2021 06:59 AM EDTUpdated 10:54 AM
Financing
Deals

Ac­tivist El­liott be­gins its long-await­ed at­tack on CEO Em­ma Walm­s­ley and a Glax­o­SmithK­line that has 'lost its way'

John Carroll

Editor & Founder

Af­ter months of mar­ket ru­mors and spec­u­la­tion, ac­tivist in­vestor El­liott has be­gun its as­sault on CEO Em­ma Walm­s­ley with a lengthy man­i­festo on the need …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

A service from the Financial Times